Smartphone‐Enabled Point‐of‐Care Biosensing Platform With Self‐Calibration for Rapid Matrix‐Resistant Detection of Multiple AMI Biomarkers in Whole Blood

Acute myocardial infarction (AMI) requires rapid diagnosis beyond conventional methods, which suffer from biological interference and complexity, limiting point-of-care (POC) application. To tackle these issues, we have devised an anthraquinone (AQ)-calibrated sensor unit coupled with smartphone-based analysis for universal detection of AMI biomarkers in untreated whole blood. Our novel dual-channel biosensing platform integrates AQ as an intrinsic reference standard, establishing a self-correction mechanism to effectively counteract hematological matrix influences. The platform enables swift quantification at pg/mL levels within 5 min without sample preprocessing, achieving detection limits of 0.3, 19.7, and 0.7 pg/mL for cTnI, Mb, and CK‑MB, respectively. The smartphone‑based intelligent analyzer automates real-time signal processing, creating a closed-loop POC diagnostic setup that shows promise for future at‑home AMI risk monitoring. This technological breakthrough showcases notable resilience to biological matrix interference while upholding analytical sensitivity comparable to clinical standards, representing a significant step toward decentralized cardiovascular emergency management.